nodes	percent_of_prediction	percent_of_DWPC	metapath
Bosutinib—SRC—colon cancer	0.285	0.533	CbGaD
Bosutinib—EGFR—colon cancer	0.191	0.358	CbGaD
Bosutinib—ABCB1—colon cancer	0.0582	0.109	CbGaD
Bosutinib—Vandetanib—SRC—colon cancer	0.0015	0.303	CrCbGaD
Bosutinib—Vandetanib—VEGFA—colon cancer	0.00119	0.241	CrCbGaD
Bosutinib—Vandetanib—EGFR—colon cancer	0.00101	0.204	CrCbGaD
Bosutinib—Gefitinib—EGFR—colon cancer	0.000956	0.193	CrCbGaD
Bosutinib—CDK2—Vinblastine—Vincristine—colon cancer	0.000937	0.259	CbGdCrCtD
Bosutinib—ABL1—Topotecan—Irinotecan—colon cancer	0.000884	0.245	CbGdCrCtD
Bosutinib—CHEK2—Vindesine—Vincristine—colon cancer	0.000662	0.183	CbGdCrCtD
Bosutinib—Rash maculo-papular—Fluorouracil—colon cancer	0.000585	0.0062	CcSEcCtD
Bosutinib—Hepatotoxicity—Capecitabine—colon cancer	0.000582	0.00618	CcSEcCtD
Bosutinib—Febrile neutropenia—Methotrexate—colon cancer	0.000557	0.0059	CcSEcCtD
Bosutinib—Renal failure acute—Irinotecan—colon cancer	0.000528	0.0056	CcSEcCtD
Bosutinib—Renal impairment—Irinotecan—colon cancer	0.000513	0.00544	CcSEcCtD
Bosutinib—Chest discomfort—Capecitabine—colon cancer	0.000508	0.00539	CcSEcCtD
Bosutinib—Gastrointestinal haemorrhage—Irinotecan—colon cancer	0.000488	0.00517	CcSEcCtD
Bosutinib—Blood bilirubin increased—Capecitabine—colon cancer	0.000476	0.00504	CcSEcCtD
Bosutinib—Gastrointestinal haemorrhage—Fluorouracil—colon cancer	0.000467	0.00496	CcSEcCtD
Bosutinib—Dehydration—Vincristine—colon cancer	0.000466	0.00494	CcSEcCtD
Bosutinib—Blood creatinine increased—Irinotecan—colon cancer	0.000457	0.00485	CcSEcCtD
Bosutinib—Dehydration—Irinotecan—colon cancer	0.000454	0.00481	CcSEcCtD
Bosutinib—Aspartate aminotransferase increased—Vincristine—colon cancer	0.000451	0.00478	CcSEcCtD
Bosutinib—Aspartate aminotransferase increased—Irinotecan—colon cancer	0.000439	0.00466	CcSEcCtD
Bosutinib—Pleural effusion—Methotrexate—colon cancer	0.000437	0.00464	CcSEcCtD
Bosutinib—Hepatotoxicity—Methotrexate—colon cancer	0.000434	0.0046	CcSEcCtD
Bosutinib—Fluid retention—Capecitabine—colon cancer	0.000427	0.00453	CcSEcCtD
Bosutinib—ERBB3—Vinblastine—Vincristine—colon cancer	0.000425	0.118	CbGdCrCtD
Bosutinib—CHEK2—Vinorelbine—Vincristine—colon cancer	0.000418	0.116	CbGdCrCtD
Bosutinib—Nasopharyngitis—Fluorouracil—colon cancer	0.000418	0.00443	CcSEcCtD
Bosutinib—Pancytopenia—Vincristine—colon cancer	0.000411	0.00436	CcSEcCtD
Bosutinib—Neutropenia—Vincristine—colon cancer	0.000405	0.00429	CcSEcCtD
Bosutinib—Neutropenia—Irinotecan—colon cancer	0.000394	0.00418	CcSEcCtD
Bosutinib—Upper respiratory tract infection—Irinotecan—colon cancer	0.000392	0.00416	CcSEcCtD
Bosutinib—Pneumonia—Vincristine—colon cancer	0.000388	0.00412	CcSEcCtD
Bosutinib—Pancytopenia—Fluorouracil—colon cancer	0.000383	0.00407	CcSEcCtD
Bosutinib—Pneumonia—Irinotecan—colon cancer	0.000378	0.00401	CcSEcCtD
Bosutinib—Upper respiratory tract infection—Fluorouracil—colon cancer	0.000375	0.00398	CcSEcCtD
Bosutinib—Hepatic function abnormal—Capecitabine—colon cancer	0.000374	0.00396	CcSEcCtD
Bosutinib—Renal failure—Irinotecan—colon cancer	0.00037	0.00392	CcSEcCtD
Bosutinib—Pneumonia—Fluorouracil—colon cancer	0.000362	0.00384	CcSEcCtD
Bosutinib—Infestation NOS—Fluorouracil—colon cancer	0.00036	0.00382	CcSEcCtD
Bosutinib—Infestation—Fluorouracil—colon cancer	0.00036	0.00382	CcSEcCtD
Bosutinib—Renal failure acute—Capecitabine—colon cancer	0.000354	0.00375	CcSEcCtD
Bosutinib—Renal impairment—Capecitabine—colon cancer	0.000343	0.00364	CcSEcCtD
Bosutinib—Urinary tract disorder—Vincristine—colon cancer	0.000342	0.00363	CcSEcCtD
Bosutinib—Respiratory failure—Methotrexate—colon cancer	0.000341	0.00362	CcSEcCtD
Bosutinib—Connective tissue disorder—Vincristine—colon cancer	0.000341	0.00361	CcSEcCtD
Bosutinib—Urethral disorder—Vincristine—colon cancer	0.00034	0.0036	CcSEcCtD
Bosutinib—Agranulocytosis—Fluorouracil—colon cancer	0.000336	0.00356	CcSEcCtD
Bosutinib—Connective tissue disorder—Irinotecan—colon cancer	0.000332	0.00352	CcSEcCtD
Bosutinib—Gastrointestinal haemorrhage—Capecitabine—colon cancer	0.000326	0.00346	CcSEcCtD
Bosutinib—Cardiac disorder—Vincristine—colon cancer	0.000322	0.00341	CcSEcCtD
Bosutinib—Face oedema—Capecitabine—colon cancer	0.000315	0.00334	CcSEcCtD
Bosutinib—Cardiac disorder—Irinotecan—colon cancer	0.000313	0.00332	CcSEcCtD
Bosutinib—Mediastinal disorder—Vincristine—colon cancer	0.000312	0.00331	CcSEcCtD
Bosutinib—Blood creatinine increased—Capecitabine—colon cancer	0.000306	0.00324	CcSEcCtD
Bosutinib—Immune system disorder—Irinotecan—colon cancer	0.000305	0.00323	CcSEcCtD
Bosutinib—Mediastinal disorder—Irinotecan—colon cancer	0.000304	0.00323	CcSEcCtD
Bosutinib—Dehydration—Capecitabine—colon cancer	0.000304	0.00322	CcSEcCtD
Bosutinib—Abdominal pain upper—Capecitabine—colon cancer	0.000298	0.00316	CcSEcCtD
Bosutinib—Aspartate aminotransferase increased—Capecitabine—colon cancer	0.000294	0.00312	CcSEcCtD
Bosutinib—Nasopharyngitis—Capecitabine—colon cancer	0.000292	0.0031	CcSEcCtD
Bosutinib—Back pain—Vincristine—colon cancer	0.000292	0.00309	CcSEcCtD
Bosutinib—Gefitinib—ABCB1—colon cancer	0.000291	0.0588	CrCbGaD
Bosutinib—Gastritis—Capecitabine—colon cancer	0.000289	0.00306	CcSEcCtD
Bosutinib—Alanine aminotransferase increased—Capecitabine—colon cancer	0.000288	0.00305	CcSEcCtD
Bosutinib—CHEK2—Vinblastine—Vincristine—colon cancer	0.000287	0.0795	CbGdCrCtD
Bosutinib—Back pain—Irinotecan—colon cancer	0.000284	0.00301	CcSEcCtD
Bosutinib—Influenza—Capecitabine—colon cancer	0.000282	0.00299	CcSEcCtD
Bosutinib—Anaemia—Vincristine—colon cancer	0.000279	0.00296	CcSEcCtD
Bosutinib—Ill-defined disorder—Irinotecan—colon cancer	0.000273	0.00289	CcSEcCtD
Bosutinib—Anaemia—Irinotecan—colon cancer	0.000272	0.00288	CcSEcCtD
Bosutinib—Bronchitis—Capecitabine—colon cancer	0.000271	0.00288	CcSEcCtD
Bosutinib—Abdominal discomfort—Capecitabine—colon cancer	0.000271	0.00287	CcSEcCtD
Bosutinib—Leukopenia—Vincristine—colon cancer	0.00027	0.00286	CcSEcCtD
Bosutinib—Pancytopenia—Capecitabine—colon cancer	0.000268	0.00284	CcSEcCtD
Bosutinib—ERBB3—lymphoid tissue—colon cancer	0.000267	0.00186	CbGeAlD
Bosutinib—MAP2K2—lymphoid tissue—colon cancer	0.000266	0.00186	CbGeAlD
Bosutinib—LYN—liver—colon cancer	0.000266	0.00186	CbGeAlD
Bosutinib—BMP2K—bone marrow—colon cancer	0.000265	0.00185	CbGeAlD
Bosutinib—CAMK2G—bone marrow—colon cancer	0.000265	0.00185	CbGeAlD
Bosutinib—Malaise—Irinotecan—colon cancer	0.000265	0.00281	CcSEcCtD
Bosutinib—VRK2—lymph node—colon cancer	0.000265	0.00185	CbGeAlD
Bosutinib—FES—lymph node—colon cancer	0.000265	0.00185	CbGeAlD
Bosutinib—MAP3K2—lymphoid tissue—colon cancer	0.000264	0.00185	CbGeAlD
Bosutinib—Neutropenia—Capecitabine—colon cancer	0.000264	0.0028	CcSEcCtD
Bosutinib—STK35—vagina—colon cancer	0.000264	0.00184	CbGeAlD
Bosutinib—ERBB3—digestive system—colon cancer	0.000264	0.00184	CbGeAlD
Bosutinib—Renal failure acute—Methotrexate—colon cancer	0.000263	0.00279	CcSEcCtD
Bosutinib—Leukopenia—Irinotecan—colon cancer	0.000263	0.00279	CcSEcCtD
Bosutinib—MAP2K2—digestive system—colon cancer	0.000263	0.00184	CbGeAlD
Bosutinib—ULK3—digestive system—colon cancer	0.000263	0.00184	CbGeAlD
Bosutinib—LRRK2—bone marrow—colon cancer	0.000263	0.00184	CbGeAlD
Bosutinib—Upper respiratory tract infection—Capecitabine—colon cancer	0.000262	0.00278	CcSEcCtD
Bosutinib—CSK—vagina—colon cancer	0.000262	0.00183	CbGeAlD
Bosutinib—YES1—smooth muscle tissue—colon cancer	0.00026	0.00182	CbGeAlD
Bosutinib—BTK—liver—colon cancer	0.00026	0.00182	CbGeAlD
Bosutinib—CSNK1A1—vagina—colon cancer	0.00026	0.00182	CbGeAlD
Bosutinib—Anaemia—Fluorouracil—colon cancer	0.00026	0.00276	CcSEcCtD
Bosutinib—SRC—epithelium—colon cancer	0.00026	0.00182	CbGeAlD
Bosutinib—SYK—lymph node—colon cancer	0.00026	0.00181	CbGeAlD
Bosutinib—TNIK—lymph node—colon cancer	0.00026	0.00181	CbGeAlD
Bosutinib—TBK1—lymphoid tissue—colon cancer	0.000259	0.00181	CbGeAlD
Bosutinib—PTK2—lymphoid tissue—colon cancer	0.000259	0.00181	CbGeAlD
Bosutinib—CLK1—vagina—colon cancer	0.000259	0.00181	CbGeAlD
Bosutinib—HCK—vagina—colon cancer	0.000259	0.00181	CbGeAlD
Bosutinib—CDK2—lymph node—colon cancer	0.000257	0.0018	CbGeAlD
Bosutinib—ABL2—vagina—colon cancer	0.000257	0.0018	CbGeAlD
Bosutinib—Myalgia—Vincristine—colon cancer	0.000257	0.00272	CcSEcCtD
Bosutinib—TNK2—liver—colon cancer	0.000257	0.00179	CbGeAlD
Bosutinib—Cough—Irinotecan—colon cancer	0.000256	0.00272	CcSEcCtD
Bosutinib—PTK2B—bone marrow—colon cancer	0.000256	0.00179	CbGeAlD
Bosutinib—TBK1—digestive system—colon cancer	0.000256	0.00179	CbGeAlD
Bosutinib—PTK2—digestive system—colon cancer	0.000256	0.00179	CbGeAlD
Bosutinib—STK26—lymph node—colon cancer	0.000255	0.00178	CbGeAlD
Bosutinib—BMP2K—vagina—colon cancer	0.000254	0.00177	CbGeAlD
Bosutinib—CAMK2G—vagina—colon cancer	0.000254	0.00177	CbGeAlD
Bosutinib—PDGFRB—embryo—colon cancer	0.000254	0.00177	CbGeAlD
Bosutinib—Pneumonia—Capecitabine—colon cancer	0.000253	0.00268	CcSEcCtD
Bosutinib—MAP4K2—liver—colon cancer	0.000253	0.00177	CbGeAlD
Bosutinib—Leukopenia—Fluorouracil—colon cancer	0.000252	0.00267	CcSEcCtD
Bosutinib—Infestation NOS—Capecitabine—colon cancer	0.000252	0.00267	CcSEcCtD
Bosutinib—Infestation—Capecitabine—colon cancer	0.000252	0.00267	CcSEcCtD
Bosutinib—LRRK2—vagina—colon cancer	0.000252	0.00176	CbGeAlD
Bosutinib—YES1—renal system—colon cancer	0.000251	0.00175	CbGeAlD
Bosutinib—SRC—smooth muscle tissue—colon cancer	0.000251	0.00175	CbGeAlD
Bosutinib—STK3—liver—colon cancer	0.00025	0.00174	CbGeAlD
Bosutinib—RPS6KB1—lymphoid tissue—colon cancer	0.000249	0.00174	CbGeAlD
Bosutinib—STK10—renal system—colon cancer	0.000248	0.00174	CbGeAlD
Bosutinib—SIK1—bone marrow—colon cancer	0.000248	0.00173	CbGeAlD
Bosutinib—IRAK4—bone marrow—colon cancer	0.000248	0.00173	CbGeAlD
Bosutinib—TAOK3—renal system—colon cancer	0.000247	0.00173	CbGeAlD
Bosutinib—FGR—lymphoid tissue—colon cancer	0.000247	0.00173	CbGeAlD
Bosutinib—Renal failure—Capecitabine—colon cancer	0.000247	0.00262	CcSEcCtD
Bosutinib—Discomfort—Irinotecan—colon cancer	0.000247	0.00262	CcSEcCtD
Bosutinib—AXL—lymphoid tissue—colon cancer	0.000246	0.00172	CbGeAlD
Bosutinib—ROCK1—liver—colon cancer	0.000246	0.00172	CbGeAlD
Bosutinib—Oedema—Vincristine—colon cancer	0.000246	0.00261	CcSEcCtD
Bosutinib—Anaphylactic shock—Vincristine—colon cancer	0.000246	0.00261	CcSEcCtD
Bosutinib—CHEK2—lymph node—colon cancer	0.000246	0.00172	CbGeAlD
Bosutinib—RPS6KB1—digestive system—colon cancer	0.000246	0.00172	CbGeAlD
Bosutinib—PTK2B—vagina—colon cancer	0.000245	0.00171	CbGeAlD
Bosutinib—Infection—Vincristine—colon cancer	0.000245	0.00259	CcSEcCtD
Bosutinib—FGR—digestive system—colon cancer	0.000244	0.00171	CbGeAlD
Bosutinib—DMPK—lymph node—colon cancer	0.000244	0.00171	CbGeAlD
Bosutinib—WEE1—lymph node—colon cancer	0.000244	0.00171	CbGeAlD
Bosutinib—MAP2K2—bone marrow—colon cancer	0.000242	0.00169	CbGeAlD
Bosutinib—ULK3—bone marrow—colon cancer	0.000242	0.00169	CbGeAlD
Bosutinib—Nervous system disorder—Vincristine—colon cancer	0.000241	0.00256	CcSEcCtD
Bosutinib—CSNK1E—vagina—colon cancer	0.000241	0.00169	CbGeAlD
Bosutinib—SRC—renal system—colon cancer	0.000241	0.00169	CbGeAlD
Bosutinib—Thrombocytopenia—Vincristine—colon cancer	0.000241	0.00256	CcSEcCtD
Bosutinib—MAP3K2—bone marrow—colon cancer	0.000241	0.00168	CbGeAlD
Bosutinib—Anaphylactic shock—Irinotecan—colon cancer	0.00024	0.00254	CcSEcCtD
Bosutinib—Oedema—Irinotecan—colon cancer	0.00024	0.00254	CcSEcCtD
Bosutinib—Myalgia—Fluorouracil—colon cancer	0.00024	0.00254	CcSEcCtD
Bosutinib—Chest pain—Fluorouracil—colon cancer	0.00024	0.00254	CcSEcCtD
Bosutinib—BMPR2—liver—colon cancer	0.000239	0.00167	CbGeAlD
Bosutinib—MAP3K7—bone marrow—colon cancer	0.000238	0.00167	CbGeAlD
Bosutinib—Infection—Irinotecan—colon cancer	0.000238	0.00253	CcSEcCtD
Bosutinib—Hepatobiliary disease—Capecitabine—colon cancer	0.000238	0.00252	CcSEcCtD
Bosutinib—IRAK4—vagina—colon cancer	0.000237	0.00166	CbGeAlD
Bosutinib—STK36—liver—colon cancer	0.000237	0.00166	CbGeAlD
Bosutinib—Discomfort—Fluorouracil—colon cancer	0.000237	0.00251	CcSEcCtD
Bosutinib—TBK1—bone marrow—colon cancer	0.000236	0.00165	CbGeAlD
Bosutinib—Nervous system disorder—Irinotecan—colon cancer	0.000235	0.00249	CcSEcCtD
Bosutinib—EPHA4—vagina—colon cancer	0.000235	0.00164	CbGeAlD
Bosutinib—Agranulocytosis—Capecitabine—colon cancer	0.000235	0.00249	CcSEcCtD
Bosutinib—Thrombocytopenia—Irinotecan—colon cancer	0.000235	0.00249	CcSEcCtD
Bosutinib—MERTK—liver—colon cancer	0.000235	0.00164	CbGeAlD
Bosutinib—STK25—lymph node—colon cancer	0.000233	0.00163	CbGeAlD
Bosutinib—EPHB4—digestive system—colon cancer	0.000233	0.00163	CbGeAlD
Bosutinib—ULK3—vagina—colon cancer	0.000232	0.00162	CbGeAlD
Bosutinib—EPHA3—lymph node—colon cancer	0.000231	0.00162	CbGeAlD
Bosutinib—EPHA2—lymphoid tissue—colon cancer	0.000231	0.00161	CbGeAlD
Bosutinib—IRAK1—bone marrow—colon cancer	0.000231	0.00161	CbGeAlD
Bosutinib—FYN—lymphoid tissue—colon cancer	0.000231	0.00161	CbGeAlD
Bosutinib—MAP4K4—liver—colon cancer	0.00023	0.00161	CbGeAlD
Bosutinib—Oedema—Fluorouracil—colon cancer	0.00023	0.00244	CcSEcCtD
Bosutinib—Anaphylactic shock—Fluorouracil—colon cancer	0.00023	0.00244	CcSEcCtD
Bosutinib—BCR—liver—colon cancer	0.000229	0.0016	CbGeAlD
Bosutinib—NUAK2—liver—colon cancer	0.000229	0.0016	CbGeAlD
Bosutinib—MAP3K7—vagina—colon cancer	0.000228	0.0016	CbGeAlD
Bosutinib—EPHA2—digestive system—colon cancer	0.000228	0.0016	CbGeAlD
Bosutinib—Infection—Fluorouracil—colon cancer	0.000228	0.00242	CcSEcCtD
Bosutinib—FYN—digestive system—colon cancer	0.000228	0.00159	CbGeAlD
Bosutinib—MAP3K12—liver—colon cancer	0.000227	0.00159	CbGeAlD
Bosutinib—RPS6KB1—bone marrow—colon cancer	0.000227	0.00158	CbGeAlD
Bosutinib—PLK2—lymph node—colon cancer	0.000227	0.00158	CbGeAlD
Bosutinib—ABL1—embryo—colon cancer	0.000226	0.00158	CbGeAlD
Bosutinib—Hepatitis—Capecitabine—colon cancer	0.000226	0.0024	CcSEcCtD
Bosutinib—TBK1—vagina—colon cancer	0.000226	0.00158	CbGeAlD
Bosutinib—PTK2—vagina—colon cancer	0.000226	0.00158	CbGeAlD
Bosutinib—MAP4K5—lymphoid tissue—colon cancer	0.000225	0.00158	CbGeAlD
Bosutinib—LCK—bone marrow—colon cancer	0.000225	0.00157	CbGeAlD
Bosutinib—FGR—bone marrow—colon cancer	0.000225	0.00157	CbGeAlD
Bosutinib—Nervous system disorder—Fluorouracil—colon cancer	0.000225	0.00239	CcSEcCtD
Bosutinib—SIK3—lymph node—colon cancer	0.000225	0.00157	CbGeAlD
Bosutinib—CSF1R—smooth muscle tissue—colon cancer	0.000225	0.00157	CbGeAlD
Bosutinib—Thrombocytopenia—Fluorouracil—colon cancer	0.000225	0.00238	CcSEcCtD
Bosutinib—Musculoskeletal discomfort—Vincristine—colon cancer	0.000224	0.00238	CcSEcCtD
Bosutinib—Urinary tract disorder—Capecitabine—colon cancer	0.000223	0.00237	CcSEcCtD
Bosutinib—Oedema peripheral—Capecitabine—colon cancer	0.000223	0.00236	CcSEcCtD
Bosutinib—MAP2K1—liver—colon cancer	0.000222	0.00155	CbGeAlD
Bosutinib—STK35—liver—colon cancer	0.000222	0.00155	CbGeAlD
Bosutinib—Connective tissue disorder—Capecitabine—colon cancer	0.000222	0.00235	CcSEcCtD
Bosutinib—Urethral disorder—Capecitabine—colon cancer	0.000221	0.00235	CcSEcCtD
Bosutinib—CSK—liver—colon cancer	0.000221	0.00154	CbGeAlD
Bosutinib—CSNK1A1—liver—colon cancer	0.00022	0.00153	CbGeAlD
Bosutinib—HCK—liver—colon cancer	0.000218	0.00152	CbGeAlD
Bosutinib—CLK1—liver—colon cancer	0.000218	0.00152	CbGeAlD
Bosutinib—RPS6KB1—vagina—colon cancer	0.000217	0.00152	CbGeAlD
Bosutinib—ABL2—liver—colon cancer	0.000217	0.00152	CbGeAlD
Bosutinib—STK4—lymph node—colon cancer	0.000217	0.00151	CbGeAlD
Bosutinib—SLK—bone marrow—colon cancer	0.000216	0.00151	CbGeAlD
Bosutinib—FGR—vagina—colon cancer	0.000216	0.00151	CbGeAlD
Bosutinib—LCK—vagina—colon cancer	0.000216	0.00151	CbGeAlD
Bosutinib—AXL—vagina—colon cancer	0.000215	0.0015	CbGeAlD
Bosutinib—EPHB4—bone marrow—colon cancer	0.000214	0.0015	CbGeAlD
Bosutinib—BMP2K—liver—colon cancer	0.000214	0.0015	CbGeAlD
Bosutinib—CAMK2G—liver—colon cancer	0.000214	0.0015	CbGeAlD
Bosutinib—CAMK1D—lymph node—colon cancer	0.000214	0.0015	CbGeAlD
Bosutinib—Decreased appetite—Vincristine—colon cancer	0.000214	0.00227	CcSEcCtD
Bosutinib—Dyspnoea—Irinotecan—colon cancer	0.000214	0.00227	CcSEcCtD
Bosutinib—Erythema multiforme—Capecitabine—colon cancer	0.000214	0.00226	CcSEcCtD
Bosutinib—Gastrointestinal disorder—Vincristine—colon cancer	0.000213	0.00225	CcSEcCtD
Bosutinib—Fatigue—Vincristine—colon cancer	0.000212	0.00225	CcSEcCtD
Bosutinib—LRRK2—liver—colon cancer	0.000212	0.00148	CbGeAlD
Bosutinib—STK24—lymph node—colon cancer	0.000212	0.00148	CbGeAlD
Bosutinib—EGFR—liver—colon cancer	0.000212	0.00148	CbGeAlD
Bosutinib—Tinnitus—Capecitabine—colon cancer	0.000211	0.00223	CcSEcCtD
Bosutinib—Pain—Vincristine—colon cancer	0.000211	0.00223	CcSEcCtD
Bosutinib—FYN—bone marrow—colon cancer	0.00021	0.00147	CbGeAlD
Bosutinib—Cardiac disorder—Capecitabine—colon cancer	0.00021	0.00222	CcSEcCtD
Bosutinib—Musculoskeletal discomfort—Fluorouracil—colon cancer	0.000209	0.00222	CcSEcCtD
Bosutinib—Decreased appetite—Irinotecan—colon cancer	0.000208	0.00221	CcSEcCtD
Bosutinib—YES1—lymphoid tissue—colon cancer	0.000208	0.00145	CbGeAlD
Bosutinib—PDGFRB—epithelium—colon cancer	0.000207	0.00145	CbGeAlD
Bosutinib—Gastrointestinal disorder—Irinotecan—colon cancer	0.000207	0.0022	CcSEcCtD
Bosutinib—SLK—vagina—colon cancer	0.000207	0.00145	CbGeAlD
Bosutinib—PTK2B—liver—colon cancer	0.000207	0.00145	CbGeAlD
Bosutinib—Fatigue—Irinotecan—colon cancer	0.000207	0.00219	CcSEcCtD
Bosutinib—STK10—lymphoid tissue—colon cancer	0.000206	0.00144	CbGeAlD
Bosutinib—YES1—digestive system—colon cancer	0.000206	0.00144	CbGeAlD
Bosutinib—TAOK3—lymphoid tissue—colon cancer	0.000206	0.00144	CbGeAlD
Bosutinib—EPHB4—vagina—colon cancer	0.000205	0.00144	CbGeAlD
Bosutinib—MAP4K5—bone marrow—colon cancer	0.000205	0.00143	CbGeAlD
Bosutinib—MAP3K3—bone marrow—colon cancer	0.000205	0.00143	CbGeAlD
Bosutinib—Pain—Irinotecan—colon cancer	0.000205	0.00217	CcSEcCtD
Bosutinib—ALK—lymph node—colon cancer	0.000205	0.00143	CbGeAlD
Bosutinib—FER—lymph node—colon cancer	0.000205	0.00143	CbGeAlD
Bosutinib—Dyspnoea—Fluorouracil—colon cancer	0.000205	0.00217	CcSEcCtD
Bosutinib—Immune system disorder—Capecitabine—colon cancer	0.000204	0.00216	CcSEcCtD
Bosutinib—STK10—digestive system—colon cancer	0.000204	0.00142	CbGeAlD
Bosutinib—Mediastinal disorder—Capecitabine—colon cancer	0.000204	0.00216	CcSEcCtD
Bosutinib—CSNK1E—liver—colon cancer	0.000203	0.00142	CbGeAlD
Bosutinib—TAOK3—digestive system—colon cancer	0.000203	0.00142	CbGeAlD
Bosutinib—EPHA2—vagina—colon cancer	0.000202	0.00141	CbGeAlD
Bosutinib—Abdominal discomfort—Methotrexate—colon cancer	0.000201	0.00214	CcSEcCtD
Bosutinib—Gastrointestinal pain—Vincristine—colon cancer	0.000201	0.00214	CcSEcCtD
Bosutinib—FYN—vagina—colon cancer	0.000201	0.00141	CbGeAlD
Bosutinib—MAP4K1—lymph node—colon cancer	0.000201	0.0014	CbGeAlD
Bosutinib—SIK1—liver—colon cancer	0.0002	0.0014	CbGeAlD
Bosutinib—IRAK4—liver—colon cancer	0.0002	0.0014	CbGeAlD
Bosutinib—SRC—lymphoid tissue—colon cancer	0.0002	0.0014	CbGeAlD
Bosutinib—BTK—lymph node—colon cancer	0.0002	0.0014	CbGeAlD
Bosutinib—Decreased appetite—Fluorouracil—colon cancer	0.0002	0.00212	CcSEcCtD
Bosutinib—Pancytopenia—Methotrexate—colon cancer	0.000199	0.00212	CcSEcCtD
Bosutinib—PDGFRB—smooth muscle tissue—colon cancer	0.000199	0.00139	CbGeAlD
Bosutinib—Gastrointestinal disorder—Fluorouracil—colon cancer	0.000198	0.0021	CcSEcCtD
Bosutinib—SRC—digestive system—colon cancer	0.000198	0.00138	CbGeAlD
Bosutinib—Feeling abnormal—Irinotecan—colon cancer	0.000198	0.0021	CcSEcCtD
Bosutinib—TNK2—lymph node—colon cancer	0.000197	0.00137	CbGeAlD
Bosutinib—MAP4K5—vagina—colon cancer	0.000197	0.00137	CbGeAlD
Bosutinib—MAP3K3—vagina—colon cancer	0.000197	0.00137	CbGeAlD
Bosutinib—Malnutrition—Capecitabine—colon cancer	0.000197	0.00209	CcSEcCtD
Bosutinib—Neutropenia—Methotrexate—colon cancer	0.000196	0.00208	CcSEcCtD
Bosutinib—Pain—Fluorouracil—colon cancer	0.000196	0.00208	CcSEcCtD
Bosutinib—ERBB3—liver—colon cancer	0.000196	0.00137	CbGeAlD
Bosutinib—Gastrointestinal pain—Irinotecan—colon cancer	0.000196	0.00208	CcSEcCtD
Bosutinib—MAP2K2—liver—colon cancer	0.000196	0.00137	CbGeAlD
Bosutinib—ULK3—liver—colon cancer	0.000196	0.00137	CbGeAlD
Bosutinib—Upper respiratory tract infection—Methotrexate—colon cancer	0.000195	0.00207	CcSEcCtD
Bosutinib—Abdominal pain—Vincristine—colon cancer	0.000195	0.00206	CcSEcCtD
Bosutinib—Body temperature increased—Vincristine—colon cancer	0.000195	0.00206	CcSEcCtD
Bosutinib—MAP3K2—liver—colon cancer	0.000194	0.00136	CbGeAlD
Bosutinib—MAP4K2—lymph node—colon cancer	0.000194	0.00136	CbGeAlD
Bosutinib—MAP3K7—liver—colon cancer	0.000193	0.00135	CbGeAlD
Bosutinib—Dysgeusia—Capecitabine—colon cancer	0.000193	0.00204	CcSEcCtD
Bosutinib—PDGFRB—renal system—colon cancer	0.000192	0.00134	CbGeAlD
Bosutinib—STK3—lymph node—colon cancer	0.000191	0.00134	CbGeAlD
Bosutinib—TBK1—liver—colon cancer	0.00019	0.00133	CbGeAlD
Bosutinib—PTK2—liver—colon cancer	0.00019	0.00133	CbGeAlD
Bosutinib—Back pain—Capecitabine—colon cancer	0.00019	0.00202	CcSEcCtD
Bosutinib—YES1—bone marrow—colon cancer	0.00019	0.00132	CbGeAlD
Bosutinib—Abdominal pain—Irinotecan—colon cancer	0.00019	0.00201	CcSEcCtD
Bosutinib—Body temperature increased—Irinotecan—colon cancer	0.00019	0.00201	CcSEcCtD
Bosutinib—Feeling abnormal—Fluorouracil—colon cancer	0.000189	0.00201	CcSEcCtD
Bosutinib—Pneumonia—Methotrexate—colon cancer	0.000188	0.002	CcSEcCtD
Bosutinib—STK10—bone marrow—colon cancer	0.000188	0.00131	CbGeAlD
Bosutinib—Infestation NOS—Methotrexate—colon cancer	0.000187	0.00199	CcSEcCtD
Bosutinib—Infestation—Methotrexate—colon cancer	0.000187	0.00199	CcSEcCtD
Bosutinib—TAOK3—bone marrow—colon cancer	0.000187	0.00131	CbGeAlD
Bosutinib—IRAK1—liver—colon cancer	0.000187	0.0013	CbGeAlD
Bosutinib—Renal failure—Methotrexate—colon cancer	0.000184	0.00195	CcSEcCtD
Bosutinib—BMPR2—lymph node—colon cancer	0.000183	0.00128	CbGeAlD
Bosutinib—RPS6KB1—liver—colon cancer	0.000183	0.00128	CbGeAlD
Bosutinib—Ill-defined disorder—Capecitabine—colon cancer	0.000182	0.00193	CcSEcCtD
Bosutinib—Urticaria—Fluorouracil—colon cancer	0.000182	0.00193	CcSEcCtD
Bosutinib—FGR—liver—colon cancer	0.000182	0.00127	CbGeAlD
Bosutinib—LCK—liver—colon cancer	0.000182	0.00127	CbGeAlD
Bosutinib—EPHB3—lymph node—colon cancer	0.000182	0.00127	CbGeAlD
Bosutinib—STK36—lymph node—colon cancer	0.000182	0.00127	CbGeAlD
Bosutinib—Anaemia—Capecitabine—colon cancer	0.000182	0.00193	CcSEcCtD
Bosutinib—YES1—vagina—colon cancer	0.000182	0.00127	CbGeAlD
Bosutinib—Body temperature increased—Fluorouracil—colon cancer	0.000182	0.00193	CcSEcCtD
Bosutinib—AXL—liver—colon cancer	0.000181	0.00127	CbGeAlD
Bosutinib—STK10—vagina—colon cancer	0.00018	0.00126	CbGeAlD
Bosutinib—MERTK—lymph node—colon cancer	0.00018	0.00126	CbGeAlD
Bosutinib—CSF1R—lymphoid tissue—colon cancer	0.00018	0.00126	CbGeAlD
Bosutinib—TAOK3—vagina—colon cancer	0.000179	0.00125	CbGeAlD
Bosutinib—ABL1—smooth muscle tissue—colon cancer	0.000178	0.00124	CbGeAlD
Bosutinib—CSF1R—digestive system—colon cancer	0.000178	0.00124	CbGeAlD
Bosutinib—Malaise—Capecitabine—colon cancer	0.000177	0.00188	CcSEcCtD
Bosutinib—Hepatobiliary disease—Methotrexate—colon cancer	0.000177	0.00188	CcSEcCtD
Bosutinib—Asthenia—Vincristine—colon cancer	0.000177	0.00187	CcSEcCtD
Bosutinib—MAP4K4—lymph node—colon cancer	0.000177	0.00123	CbGeAlD
Bosutinib—Leukopenia—Capecitabine—colon cancer	0.000176	0.00187	CcSEcCtD
Bosutinib—BCR—lymph node—colon cancer	0.000175	0.00123	CbGeAlD
Bosutinib—NUAK2—lymph node—colon cancer	0.000175	0.00123	CbGeAlD
Bosutinib—Agranulocytosis—Methotrexate—colon cancer	0.000175	0.00185	CcSEcCtD
Bosutinib—SLK—liver—colon cancer	0.000175	0.00122	CbGeAlD
Bosutinib—MAP3K12—lymph node—colon cancer	0.000174	0.00122	CbGeAlD
Bosutinib—EPHB4—liver—colon cancer	0.000173	0.00121	CbGeAlD
Bosutinib—Asthenia—Irinotecan—colon cancer	0.000172	0.00182	CcSEcCtD
Bosutinib—Cough—Capecitabine—colon cancer	0.000172	0.00182	CcSEcCtD
Bosutinib—ABL1—renal system—colon cancer	0.000171	0.0012	CbGeAlD
Bosutinib—STK35—lymph node—colon cancer	0.000171	0.00119	CbGeAlD
Bosutinib—MAP2K1—lymph node—colon cancer	0.000171	0.00119	CbGeAlD
Bosutinib—EPHA2—liver—colon cancer	0.00017	0.00119	CbGeAlD
Bosutinib—FYN—liver—colon cancer	0.00017	0.00119	CbGeAlD
Bosutinib—CSK—lymph node—colon cancer	0.000169	0.00118	CbGeAlD
Bosutinib—Diarrhoea—Vincristine—colon cancer	0.000168	0.00179	CcSEcCtD
Bosutinib—CSNK1A1—lymph node—colon cancer	0.000168	0.00118	CbGeAlD
Bosutinib—Hepatitis—Methotrexate—colon cancer	0.000168	0.00178	CcSEcCtD
Bosutinib—Myalgia—Capecitabine—colon cancer	0.000167	0.00178	CcSEcCtD
Bosutinib—Arthralgia—Capecitabine—colon cancer	0.000167	0.00178	CcSEcCtD
Bosutinib—Chest pain—Capecitabine—colon cancer	0.000167	0.00178	CcSEcCtD
Bosutinib—HCK—lymph node—colon cancer	0.000167	0.00117	CbGeAlD
Bosutinib—CLK1—lymph node—colon cancer	0.000167	0.00117	CbGeAlD
Bosutinib—Unspecified disorder of skin and subcutaneous tissue—Capecitabine—colon cancer	0.000166	0.00176	CcSEcCtD
Bosutinib—ABL2—lymph node—colon cancer	0.000166	0.00116	CbGeAlD
Bosutinib—Urinary tract disorder—Methotrexate—colon cancer	0.000166	0.00176	CcSEcCtD
Bosutinib—MAP3K3—liver—colon cancer	0.000166	0.00116	CbGeAlD
Bosutinib—MAP4K5—liver—colon cancer	0.000166	0.00116	CbGeAlD
Bosutinib—Discomfort—Capecitabine—colon cancer	0.000165	0.00175	CcSEcCtD
Bosutinib—Urethral disorder—Methotrexate—colon cancer	0.000165	0.00175	CcSEcCtD
Bosutinib—BMP2K—lymph node—colon cancer	0.000164	0.00115	CbGeAlD
Bosutinib—CAMK2G—lymph node—colon cancer	0.000164	0.00115	CbGeAlD
Bosutinib—Diarrhoea—Irinotecan—colon cancer	0.000164	0.00174	CcSEcCtD
Bosutinib—CSF1R—bone marrow—colon cancer	0.000164	0.00114	CbGeAlD
Bosutinib—Dizziness—Vincristine—colon cancer	0.000163	0.00173	CcSEcCtD
Bosutinib—LRRK2—lymph node—colon cancer	0.000163	0.00114	CbGeAlD
Bosutinib—Pruritus—Fluorouracil—colon cancer	0.000162	0.00172	CcSEcCtD
Bosutinib—EGFR—lymph node—colon cancer	0.000162	0.00113	CbGeAlD
Bosutinib—MAP2K5—vagina—colon cancer	0.000161	0.00112	CbGeAlD
Bosutinib—Oedema—Capecitabine—colon cancer	0.00016	0.0017	CcSEcCtD
Bosutinib—PDGFRB—lymphoid tissue—colon cancer	0.000159	0.00111	CbGeAlD
Bosutinib—Infection—Capecitabine—colon cancer	0.000159	0.00169	CcSEcCtD
Bosutinib—Erythema multiforme—Methotrexate—colon cancer	0.000159	0.00169	CcSEcCtD
Bosutinib—PTK2B—lymph node—colon cancer	0.000159	0.00111	CbGeAlD
Bosutinib—Dizziness—Irinotecan—colon cancer	0.000159	0.00168	CcSEcCtD
Bosutinib—PDGFRB—digestive system—colon cancer	0.000158	0.0011	CbGeAlD
Bosutinib—Nervous system disorder—Capecitabine—colon cancer	0.000157	0.00167	CcSEcCtD
Bosutinib—Diarrhoea—Fluorouracil—colon cancer	0.000157	0.00167	CcSEcCtD
Bosutinib—Thrombocytopenia—Capecitabine—colon cancer	0.000157	0.00167	CcSEcCtD
Bosutinib—CSF1R—vagina—colon cancer	0.000157	0.0011	CbGeAlD
Bosutinib—Tinnitus—Methotrexate—colon cancer	0.000157	0.00166	CcSEcCtD
Bosutinib—Vomiting—Vincristine—colon cancer	0.000157	0.00166	CcSEcCtD
Bosutinib—Cardiac disorder—Methotrexate—colon cancer	0.000156	0.00166	CcSEcCtD
Bosutinib—CSNK1E—lymph node—colon cancer	0.000156	0.00109	CbGeAlD
Bosutinib—Skin disorder—Capecitabine—colon cancer	0.000156	0.00165	CcSEcCtD
Bosutinib—Rash—Vincristine—colon cancer	0.000155	0.00165	CcSEcCtD
Bosutinib—Dermatitis—Vincristine—colon cancer	0.000155	0.00164	CcSEcCtD
Bosutinib—Headache—Vincristine—colon cancer	0.000154	0.00164	CcSEcCtD
Bosutinib—SIK1—lymph node—colon cancer	0.000154	0.00107	CbGeAlD
Bosutinib—IRAK4—lymph node—colon cancer	0.000154	0.00107	CbGeAlD
Bosutinib—YES1—liver—colon cancer	0.000153	0.00107	CbGeAlD
Bosutinib—Vomiting—Irinotecan—colon cancer	0.000152	0.00162	CcSEcCtD
Bosutinib—EPHA4—lymph node—colon cancer	0.000152	0.00106	CbGeAlD
Bosutinib—Immune system disorder—Methotrexate—colon cancer	0.000152	0.00161	CcSEcCtD
Bosutinib—Dizziness—Fluorouracil—colon cancer	0.000152	0.00161	CcSEcCtD
Bosutinib—STK10—liver—colon cancer	0.000152	0.00106	CbGeAlD
Bosutinib—Mediastinal disorder—Methotrexate—colon cancer	0.000152	0.00161	CcSEcCtD
Bosutinib—TAOK3—liver—colon cancer	0.000151	0.00106	CbGeAlD
Bosutinib—Rash—Irinotecan—colon cancer	0.000151	0.0016	CcSEcCtD
Bosutinib—Dermatitis—Irinotecan—colon cancer	0.000151	0.0016	CcSEcCtD
Bosutinib—ERBB3—lymph node—colon cancer	0.000151	0.00105	CbGeAlD
Bosutinib—Headache—Irinotecan—colon cancer	0.00015	0.00159	CcSEcCtD
Bosutinib—ULK3—lymph node—colon cancer	0.00015	0.00105	CbGeAlD
Bosutinib—MAP2K2—lymph node—colon cancer	0.00015	0.00105	CbGeAlD
Bosutinib—MAP3K2—lymph node—colon cancer	0.000149	0.00104	CbGeAlD
Bosutinib—MAP3K7—lymph node—colon cancer	0.000148	0.00103	CbGeAlD
Bosutinib—SRC—liver—colon cancer	0.000147	0.00103	CbGeAlD
Bosutinib—Malnutrition—Methotrexate—colon cancer	0.000146	0.00155	CcSEcCtD
Bosutinib—Nausea—Vincristine—colon cancer	0.000146	0.00155	CcSEcCtD
Bosutinib—Musculoskeletal discomfort—Capecitabine—colon cancer	0.000146	0.00155	CcSEcCtD
Bosutinib—TBK1—lymph node—colon cancer	0.000146	0.00102	CbGeAlD
Bosutinib—PTK2—lymph node—colon cancer	0.000146	0.00102	CbGeAlD
Bosutinib—Vomiting—Fluorouracil—colon cancer	0.000146	0.00155	CcSEcCtD
Bosutinib—PDGFRB—bone marrow—colon cancer	0.000145	0.00101	CbGeAlD
Bosutinib—Rash—Fluorouracil—colon cancer	0.000145	0.00154	CcSEcCtD
Bosutinib—Dermatitis—Fluorouracil—colon cancer	0.000145	0.00153	CcSEcCtD
Bosutinib—Headache—Fluorouracil—colon cancer	0.000144	0.00153	CcSEcCtD
Bosutinib—Dysgeusia—Methotrexate—colon cancer	0.000143	0.00152	CcSEcCtD
Bosutinib—IRAK1—lymph node—colon cancer	0.000143	0.001	CbGeAlD
Bosutinib—Dyspnoea—Capecitabine—colon cancer	0.000143	0.00152	CcSEcCtD
Bosutinib—Nausea—Irinotecan—colon cancer	0.000142	0.00151	CcSEcCtD
Bosutinib—ABL1—lymphoid tissue—colon cancer	0.000142	0.000993	CbGeAlD
Bosutinib—Back pain—Methotrexate—colon cancer	0.000142	0.0015	CcSEcCtD
Bosutinib—RPS6KB1—lymph node—colon cancer	0.00014	0.000982	CbGeAlD
Bosutinib—ABL1—digestive system—colon cancer	0.00014	0.000981	CbGeAlD
Bosutinib—LCK—lymph node—colon cancer	0.00014	0.000976	CbGeAlD
Bosutinib—FGR—lymph node—colon cancer	0.00014	0.000976	CbGeAlD
Bosutinib—Decreased appetite—Capecitabine—colon cancer	0.000139	0.00148	CcSEcCtD
Bosutinib—PDGFRB—vagina—colon cancer	0.000139	0.000972	CbGeAlD
Bosutinib—AXL—lymph node—colon cancer	0.000139	0.000972	CbGeAlD
Bosutinib—Gastrointestinal disorder—Capecitabine—colon cancer	0.000139	0.00147	CcSEcCtD
Bosutinib—Fatigue—Capecitabine—colon cancer	0.000138	0.00147	CcSEcCtD
Bosutinib—Pain—Capecitabine—colon cancer	0.000137	0.00146	CcSEcCtD
Bosutinib—Nausea—Fluorouracil—colon cancer	0.000136	0.00145	CcSEcCtD
Bosutinib—Ill-defined disorder—Methotrexate—colon cancer	0.000136	0.00144	CcSEcCtD
Bosutinib—MAP2K5—liver—colon cancer	0.000136	0.000947	CbGeAlD
Bosutinib—Anaemia—Methotrexate—colon cancer	0.000135	0.00143	CcSEcCtD
Bosutinib—SLK—lymph node—colon cancer	0.000134	0.000935	CbGeAlD
Bosutinib—EPHB4—lymph node—colon cancer	0.000133	0.000929	CbGeAlD
Bosutinib—CSF1R—liver—colon cancer	0.000132	0.000925	CbGeAlD
Bosutinib—Feeling abnormal—Capecitabine—colon cancer	0.000132	0.0014	CcSEcCtD
Bosutinib—Malaise—Methotrexate—colon cancer	0.000132	0.0014	CcSEcCtD
Bosutinib—Gastrointestinal pain—Capecitabine—colon cancer	0.000131	0.00139	CcSEcCtD
Bosutinib—Leukopenia—Methotrexate—colon cancer	0.000131	0.00139	CcSEcCtD
Bosutinib—EPHA2—lymph node—colon cancer	0.00013	0.000911	CbGeAlD
Bosutinib—FYN—lymph node—colon cancer	0.00013	0.00091	CbGeAlD
Bosutinib—ABL1—bone marrow—colon cancer	0.000129	0.000904	CbGeAlD
Bosutinib—Cough—Methotrexate—colon cancer	0.000128	0.00135	CcSEcCtD
Bosutinib—Urticaria—Capecitabine—colon cancer	0.000127	0.00135	CcSEcCtD
Bosutinib—MAP4K5—lymph node—colon cancer	0.000127	0.000889	CbGeAlD
Bosutinib—MAP3K3—lymph node—colon cancer	0.000127	0.000889	CbGeAlD
Bosutinib—Abdominal pain—Capecitabine—colon cancer	0.000127	0.00135	CcSEcCtD
Bosutinib—Body temperature increased—Capecitabine—colon cancer	0.000127	0.00135	CcSEcCtD
Bosutinib—Chest pain—Methotrexate—colon cancer	0.000125	0.00132	CcSEcCtD
Bosutinib—Arthralgia—Methotrexate—colon cancer	0.000125	0.00132	CcSEcCtD
Bosutinib—Myalgia—Methotrexate—colon cancer	0.000125	0.00132	CcSEcCtD
Bosutinib—ABL1—vagina—colon cancer	0.000124	0.000866	CbGeAlD
Bosutinib—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—colon cancer	0.000124	0.00131	CcSEcCtD
Bosutinib—Discomfort—Methotrexate—colon cancer	0.000123	0.00131	CcSEcCtD
Bosutinib—Anaphylactic shock—Methotrexate—colon cancer	0.000119	0.00127	CcSEcCtD
Bosutinib—Infection—Methotrexate—colon cancer	0.000119	0.00126	CcSEcCtD
Bosutinib—ABCB1—blood vessel—colon cancer	0.000118	0.000824	CbGeAlD
Bosutinib—YES1—lymph node—colon cancer	0.000117	0.000821	CbGeAlD
Bosutinib—PDGFRB—liver—colon cancer	0.000117	0.00082	CbGeAlD
Bosutinib—Nervous system disorder—Methotrexate—colon cancer	0.000117	0.00124	CcSEcCtD
Bosutinib—Thrombocytopenia—Methotrexate—colon cancer	0.000117	0.00124	CcSEcCtD
Bosutinib—STK10—lymph node—colon cancer	0.000116	0.000813	CbGeAlD
Bosutinib—Skin disorder—Methotrexate—colon cancer	0.000116	0.00123	CcSEcCtD
Bosutinib—TAOK3—lymph node—colon cancer	0.000116	0.00081	CbGeAlD
Bosutinib—Asthenia—Capecitabine—colon cancer	0.000115	0.00122	CcSEcCtD
Bosutinib—Pruritus—Capecitabine—colon cancer	0.000114	0.0012	CcSEcCtD
Bosutinib—SRC—lymph node—colon cancer	0.000113	0.00079	CbGeAlD
Bosutinib—Diarrhoea—Capecitabine—colon cancer	0.00011	0.00116	CcSEcCtD
Bosutinib—Musculoskeletal discomfort—Methotrexate—colon cancer	0.000109	0.00115	CcSEcCtD
Bosutinib—Dyspnoea—Methotrexate—colon cancer	0.000106	0.00113	CcSEcCtD
Bosutinib—Dizziness—Capecitabine—colon cancer	0.000106	0.00113	CcSEcCtD
Bosutinib—ABL1—liver—colon cancer	0.000105	0.000731	CbGeAlD
Bosutinib—MAP2K5—lymph node—colon cancer	0.000104	0.000726	CbGeAlD
Bosutinib—Decreased appetite—Methotrexate—colon cancer	0.000104	0.0011	CcSEcCtD
Bosutinib—Gastrointestinal disorder—Methotrexate—colon cancer	0.000103	0.00109	CcSEcCtD
Bosutinib—Fatigue—Methotrexate—colon cancer	0.000103	0.00109	CcSEcCtD
Bosutinib—Pain—Methotrexate—colon cancer	0.000102	0.00108	CcSEcCtD
Bosutinib—Vomiting—Capecitabine—colon cancer	0.000102	0.00108	CcSEcCtD
Bosutinib—CSF1R—lymph node—colon cancer	0.000101	0.000709	CbGeAlD
Bosutinib—Rash—Capecitabine—colon cancer	0.000101	0.00107	CcSEcCtD
Bosutinib—Dermatitis—Capecitabine—colon cancer	0.000101	0.00107	CcSEcCtD
Bosutinib—Headache—Capecitabine—colon cancer	0.000101	0.00107	CcSEcCtD
Bosutinib—Feeling abnormal—Methotrexate—colon cancer	9.84e-05	0.00104	CcSEcCtD
Bosutinib—Gastrointestinal pain—Methotrexate—colon cancer	9.77e-05	0.00104	CcSEcCtD
Bosutinib—Nausea—Capecitabine—colon cancer	9.53e-05	0.00101	CcSEcCtD
Bosutinib—Urticaria—Methotrexate—colon cancer	9.49e-05	0.00101	CcSEcCtD
Bosutinib—Body temperature increased—Methotrexate—colon cancer	9.44e-05	0.001	CcSEcCtD
Bosutinib—Abdominal pain—Methotrexate—colon cancer	9.44e-05	0.001	CcSEcCtD
Bosutinib—PDGFRB—lymph node—colon cancer	9e-05	0.000629	CbGeAlD
Bosutinib—Asthenia—Methotrexate—colon cancer	8.57e-05	0.000909	CcSEcCtD
Bosutinib—Pruritus—Methotrexate—colon cancer	8.45e-05	0.000896	CcSEcCtD
Bosutinib—Diarrhoea—Methotrexate—colon cancer	8.17e-05	0.000867	CcSEcCtD
Bosutinib—ABL1—lymph node—colon cancer	8.02e-05	0.00056	CbGeAlD
Bosutinib—Dizziness—Methotrexate—colon cancer	7.9e-05	0.000838	CcSEcCtD
Bosutinib—Vomiting—Methotrexate—colon cancer	7.6e-05	0.000806	CcSEcCtD
Bosutinib—Rash—Methotrexate—colon cancer	7.53e-05	0.000799	CcSEcCtD
Bosutinib—Dermatitis—Methotrexate—colon cancer	7.52e-05	0.000798	CcSEcCtD
Bosutinib—CYP3A4—renal system—colon cancer	7.52e-05	0.000525	CbGeAlD
Bosutinib—Headache—Methotrexate—colon cancer	7.48e-05	0.000794	CcSEcCtD
Bosutinib—Nausea—Methotrexate—colon cancer	7.1e-05	0.000753	CcSEcCtD
Bosutinib—ABCB1—embryo—colon cancer	7.03e-05	0.000491	CbGeAlD
Bosutinib—CYP3A4—digestive system—colon cancer	6.17e-05	0.000431	CbGeAlD
Bosutinib—ABCB1—epithelium—colon cancer	5.74e-05	0.000401	CbGeAlD
Bosutinib—ABCB1—renal system—colon cancer	5.32e-05	0.000372	CbGeAlD
Bosutinib—CYP3A4—liver—colon cancer	4.59e-05	0.000321	CbGeAlD
Bosutinib—ABCB1—lymphoid tissue—colon cancer	4.42e-05	0.000309	CbGeAlD
Bosutinib—ABCB1—digestive system—colon cancer	4.37e-05	0.000305	CbGeAlD
Bosutinib—ABCB1—bone marrow—colon cancer	4.02e-05	0.000281	CbGeAlD
Bosutinib—ABCB1—vagina—colon cancer	3.86e-05	0.000269	CbGeAlD
Bosutinib—ABCB1—liver—colon cancer	3.25e-05	0.000227	CbGeAlD
Bosutinib—ABCB1—lymph node—colon cancer	2.49e-05	0.000174	CbGeAlD
Bosutinib—FYN—Immune System—PIK3CA—colon cancer	1.4e-06	6.37e-06	CbGpPWpGaD
Bosutinib—MAP2K2—Signaling Pathways—CTNNB1—colon cancer	1.4e-06	6.37e-06	CbGpPWpGaD
Bosutinib—ROCK1—Signaling Pathways—HRAS—colon cancer	1.4e-06	6.37e-06	CbGpPWpGaD
Bosutinib—MAP2K1—Disease—KRAS—colon cancer	1.4e-06	6.37e-06	CbGpPWpGaD
Bosutinib—SRC—Immune System—EP300—colon cancer	1.4e-06	6.35e-06	CbGpPWpGaD
Bosutinib—MAP3K7—Signaling Pathways—NRAS—colon cancer	1.39e-06	6.34e-06	CbGpPWpGaD
Bosutinib—MAP2K1—Immune System—PIK3CA—colon cancer	1.39e-06	6.34e-06	CbGpPWpGaD
Bosutinib—MAP3K7—Immune System—AKT1—colon cancer	1.39e-06	6.33e-06	CbGpPWpGaD
Bosutinib—SRC—Adaptive Immune System—AKT1—colon cancer	1.39e-06	6.33e-06	CbGpPWpGaD
Bosutinib—LYN—Signaling Pathways—CASP3—colon cancer	1.39e-06	6.31e-06	CbGpPWpGaD
Bosutinib—SRC—Disease—CTNNB1—colon cancer	1.39e-06	6.31e-06	CbGpPWpGaD
Bosutinib—PDGFRB—Signaling Pathways—CCND1—colon cancer	1.38e-06	6.28e-06	CbGpPWpGaD
Bosutinib—IRAK1—Signaling Pathways—MYC—colon cancer	1.38e-06	6.27e-06	CbGpPWpGaD
Bosutinib—MAP2K2—Immune System—HRAS—colon cancer	1.38e-06	6.27e-06	CbGpPWpGaD
Bosutinib—ABCB1—Metabolism—TYMS—colon cancer	1.38e-06	6.27e-06	CbGpPWpGaD
Bosutinib—IRAK1—Signaling Pathways—TGFB1—colon cancer	1.38e-06	6.26e-06	CbGpPWpGaD
Bosutinib—MAP2K2—Disease—PIK3CA—colon cancer	1.38e-06	6.26e-06	CbGpPWpGaD
Bosutinib—MAP2K2—Signaling Pathways—CDKN1A—colon cancer	1.37e-06	6.22e-06	CbGpPWpGaD
Bosutinib—PDGFRB—Signaling Pathways—CTNNB1—colon cancer	1.37e-06	6.22e-06	CbGpPWpGaD
Bosutinib—FYN—Signaling Pathways—CASP3—colon cancer	1.37e-06	6.22e-06	CbGpPWpGaD
Bosutinib—LCK—Disease—NRAS—colon cancer	1.36e-06	6.2e-06	CbGpPWpGaD
Bosutinib—PTK2—Signaling Pathways—KRAS—colon cancer	1.36e-06	6.19e-06	CbGpPWpGaD
Bosutinib—ERBB3—Signaling Pathways—TP53—colon cancer	1.36e-06	6.19e-06	CbGpPWpGaD
Bosutinib—MAP2K1—Signaling Pathways—CASP3—colon cancer	1.36e-06	6.18e-06	CbGpPWpGaD
Bosutinib—SRC—Disease—CDKN1A—colon cancer	1.36e-06	6.16e-06	CbGpPWpGaD
Bosutinib—LYN—Signaling Pathways—CCND1—colon cancer	1.35e-06	6.15e-06	CbGpPWpGaD
Bosutinib—RPS6KB1—Signaling Pathways—HRAS—colon cancer	1.35e-06	6.14e-06	CbGpPWpGaD
Bosutinib—MAP2K5—Signaling Pathways—HRAS—colon cancer	1.35e-06	6.14e-06	CbGpPWpGaD
Bosutinib—IRAK1—Signaling Pathways—EGFR—colon cancer	1.35e-06	6.13e-06	CbGpPWpGaD
Bosutinib—PDGFRB—Immune System—HRAS—colon cancer	1.35e-06	6.12e-06	CbGpPWpGaD
Bosutinib—LCK—Immune System—EGFR—colon cancer	1.35e-06	6.11e-06	CbGpPWpGaD
Bosutinib—SRC—Signaling Pathways—BRAF—colon cancer	1.34e-06	6.11e-06	CbGpPWpGaD
Bosutinib—YES1—Signaling Pathways—KRAS—colon cancer	1.34e-06	6.11e-06	CbGpPWpGaD
Bosutinib—PDGFRB—Disease—PIK3CA—colon cancer	1.34e-06	6.1e-06	CbGpPWpGaD
Bosutinib—LYN—Signaling Pathways—CTNNB1—colon cancer	1.34e-06	6.09e-06	CbGpPWpGaD
Bosutinib—PDGFRB—Signaling Pathways—CDKN1A—colon cancer	1.34e-06	6.07e-06	CbGpPWpGaD
Bosutinib—MAP2K2—Signaling by GPCR—AKT1—colon cancer	1.33e-06	6.06e-06	CbGpPWpGaD
Bosutinib—FYN—Signaling Pathways—CCND1—colon cancer	1.33e-06	6.05e-06	CbGpPWpGaD
Bosutinib—EGFR—Signaling by GPCR—PIK3CA—colon cancer	1.33e-06	6.03e-06	CbGpPWpGaD
Bosutinib—MAP2K1—Signaling Pathways—CCND1—colon cancer	1.32e-06	6.02e-06	CbGpPWpGaD
Bosutinib—EGFR—Immune System—KRAS—colon cancer	1.32e-06	5.99e-06	CbGpPWpGaD
Bosutinib—FYN—Signaling Pathways—CTNNB1—colon cancer	1.32e-06	5.99e-06	CbGpPWpGaD
Bosutinib—LYN—Immune System—HRAS—colon cancer	1.32e-06	5.99e-06	CbGpPWpGaD
Bosutinib—EGFR—Disease—MYC—colon cancer	1.32e-06	5.99e-06	CbGpPWpGaD
Bosutinib—EGFR—Disease—TGFB1—colon cancer	1.31e-06	5.97e-06	CbGpPWpGaD
Bosutinib—ABL1—Immune System—HRAS—colon cancer	1.31e-06	5.96e-06	CbGpPWpGaD
Bosutinib—MAP2K1—Signaling Pathways—CTNNB1—colon cancer	1.31e-06	5.96e-06	CbGpPWpGaD
Bosutinib—LYN—Signaling Pathways—CDKN1A—colon cancer	1.31e-06	5.95e-06	CbGpPWpGaD
Bosutinib—SRC—Immune System—NRAS—colon cancer	1.31e-06	5.94e-06	CbGpPWpGaD
Bosutinib—ERBB4—Signaling Pathways—AKT1—colon cancer	1.3e-06	5.93e-06	CbGpPWpGaD
Bosutinib—MAP2K2—Signaling Pathways—EP300—colon cancer	1.3e-06	5.92e-06	CbGpPWpGaD
Bosutinib—ERBB3—Signaling Pathways—HRAS—colon cancer	1.3e-06	5.92e-06	CbGpPWpGaD
Bosutinib—MAP3K7—Signaling Pathways—MYC—colon cancer	1.3e-06	5.9e-06	CbGpPWpGaD
Bosutinib—FYN—Immune System—HRAS—colon cancer	1.3e-06	5.9e-06	CbGpPWpGaD
Bosutinib—MAP3K7—Signaling Pathways—TGFB1—colon cancer	1.3e-06	5.89e-06	CbGpPWpGaD
Bosutinib—FYN—Disease—PIK3CA—colon cancer	1.29e-06	5.88e-06	CbGpPWpGaD
Bosutinib—MAP2K1—Immune System—HRAS—colon cancer	1.29e-06	5.86e-06	CbGpPWpGaD
Bosutinib—SRC—Disease—EP300—colon cancer	1.29e-06	5.86e-06	CbGpPWpGaD
Bosutinib—FYN—Signaling Pathways—CDKN1A—colon cancer	1.29e-06	5.85e-06	CbGpPWpGaD
Bosutinib—MAP2K1—Disease—PIK3CA—colon cancer	1.29e-06	5.85e-06	CbGpPWpGaD
Bosutinib—PTK2B—Signaling Pathways—AKT1—colon cancer	1.29e-06	5.84e-06	CbGpPWpGaD
Bosutinib—MAP2K1—Signaling Pathways—CDKN1A—colon cancer	1.28e-06	5.82e-06	CbGpPWpGaD
Bosutinib—IRAK1—Signaling Pathways—KRAS—colon cancer	1.28e-06	5.79e-06	CbGpPWpGaD
Bosutinib—MAP2K2—Disease—HRAS—colon cancer	1.27e-06	5.79e-06	CbGpPWpGaD
Bosutinib—PDGFRB—Signaling Pathways—EP300—colon cancer	1.27e-06	5.78e-06	CbGpPWpGaD
Bosutinib—MAP3K7—Signaling Pathways—EGFR—colon cancer	1.27e-06	5.78e-06	CbGpPWpGaD
Bosutinib—LCK—Immune System—KRAS—colon cancer	1.27e-06	5.78e-06	CbGpPWpGaD
Bosutinib—LCK—Disease—MYC—colon cancer	1.27e-06	5.77e-06	CbGpPWpGaD
Bosutinib—MAP2K2—Signaling Pathways—SRC—colon cancer	1.27e-06	5.76e-06	CbGpPWpGaD
Bosutinib—LCK—Disease—TGFB1—colon cancer	1.27e-06	5.76e-06	CbGpPWpGaD
Bosutinib—PTK2—Signaling Pathways—PIK3CA—colon cancer	1.25e-06	5.69e-06	CbGpPWpGaD
Bosutinib—MAP2K1—Signaling by GPCR—AKT1—colon cancer	1.25e-06	5.67e-06	CbGpPWpGaD
Bosutinib—LYN—Signaling Pathways—EP300—colon cancer	1.24e-06	5.66e-06	CbGpPWpGaD
Bosutinib—PDGFRB—Disease—HRAS—colon cancer	1.24e-06	5.65e-06	CbGpPWpGaD
Bosutinib—LCK—Disease—EGFR—colon cancer	1.24e-06	5.64e-06	CbGpPWpGaD
Bosutinib—ROCK1—Signaling Pathways—AKT1—colon cancer	1.24e-06	5.62e-06	CbGpPWpGaD
Bosutinib—PDGFRB—Signaling Pathways—SRC—colon cancer	1.24e-06	5.62e-06	CbGpPWpGaD
Bosutinib—YES1—Signaling Pathways—PIK3CA—colon cancer	1.24e-06	5.61e-06	CbGpPWpGaD
Bosutinib—MAP2K2—Signaling Pathways—VEGFA—colon cancer	1.23e-06	5.61e-06	CbGpPWpGaD
Bosutinib—EGFR—Signaling by GPCR—HRAS—colon cancer	1.23e-06	5.58e-06	CbGpPWpGaD
Bosutinib—FYN—Signaling Pathways—EP300—colon cancer	1.23e-06	5.57e-06	CbGpPWpGaD
Bosutinib—MAP2K1—Signaling Pathways—EP300—colon cancer	1.22e-06	5.54e-06	CbGpPWpGaD
Bosutinib—MAP2K2—Signaling Pathways—NRAS—colon cancer	1.22e-06	5.54e-06	CbGpPWpGaD
Bosutinib—MAP2K2—Immune System—AKT1—colon cancer	1.22e-06	5.53e-06	CbGpPWpGaD
Bosutinib—EGFR—Disease—KRAS—colon cancer	1.22e-06	5.53e-06	CbGpPWpGaD
Bosutinib—PTK2—Signaling Pathways—TP53—colon cancer	1.21e-06	5.51e-06	CbGpPWpGaD
Bosutinib—EGFR—Immune System—PIK3CA—colon cancer	1.21e-06	5.51e-06	CbGpPWpGaD
Bosutinib—LYN—Signaling Pathways—SRC—colon cancer	1.21e-06	5.5e-06	CbGpPWpGaD
Bosutinib—SRC—Disease—NRAS—colon cancer	1.21e-06	5.48e-06	CbGpPWpGaD
Bosutinib—PDGFRB—Signaling Pathways—VEGFA—colon cancer	1.2e-06	5.47e-06	CbGpPWpGaD
Bosutinib—MAP3K7—Signaling Pathways—KRAS—colon cancer	1.2e-06	5.46e-06	CbGpPWpGaD
Bosutinib—FYN—Disease—HRAS—colon cancer	1.2e-06	5.44e-06	CbGpPWpGaD
Bosutinib—YES1—Signaling Pathways—TP53—colon cancer	1.19e-06	5.43e-06	CbGpPWpGaD
Bosutinib—RPS6KB1—Signaling Pathways—AKT1—colon cancer	1.19e-06	5.42e-06	CbGpPWpGaD
Bosutinib—MAP2K5—Signaling Pathways—AKT1—colon cancer	1.19e-06	5.42e-06	CbGpPWpGaD
Bosutinib—FYN—Signaling Pathways—SRC—colon cancer	1.19e-06	5.42e-06	CbGpPWpGaD
Bosutinib—MAP2K1—Disease—HRAS—colon cancer	1.19e-06	5.41e-06	CbGpPWpGaD
Bosutinib—SRC—Immune System—EGFR—colon cancer	1.19e-06	5.41e-06	CbGpPWpGaD
Bosutinib—PDGFRB—Signaling Pathways—NRAS—colon cancer	1.19e-06	5.41e-06	CbGpPWpGaD
Bosutinib—PDGFRB—Immune System—AKT1—colon cancer	1.19e-06	5.4e-06	CbGpPWpGaD
Bosutinib—MAP2K1—Signaling Pathways—SRC—colon cancer	1.19e-06	5.39e-06	CbGpPWpGaD
Bosutinib—EGFR—Signaling Pathways—CASP3—colon cancer	1.18e-06	5.37e-06	CbGpPWpGaD
Bosutinib—LYN—Signaling Pathways—VEGFA—colon cancer	1.18e-06	5.36e-06	CbGpPWpGaD
Bosutinib—LCK—Disease—KRAS—colon cancer	1.17e-06	5.33e-06	CbGpPWpGaD
Bosutinib—IRAK1—Signaling Pathways—PIK3CA—colon cancer	1.17e-06	5.32e-06	CbGpPWpGaD
Bosutinib—LCK—Immune System—PIK3CA—colon cancer	1.17e-06	5.31e-06	CbGpPWpGaD
Bosutinib—LYN—Signaling Pathways—NRAS—colon cancer	1.16e-06	5.29e-06	CbGpPWpGaD
Bosutinib—LYN—Immune System—AKT1—colon cancer	1.16e-06	5.29e-06	CbGpPWpGaD
Bosutinib—FYN—Signaling Pathways—VEGFA—colon cancer	1.16e-06	5.28e-06	CbGpPWpGaD
Bosutinib—PTK2—Signaling Pathways—HRAS—colon cancer	1.16e-06	5.27e-06	CbGpPWpGaD
Bosutinib—ABL1—Immune System—AKT1—colon cancer	1.16e-06	5.26e-06	CbGpPWpGaD
Bosutinib—MAP2K1—Signaling Pathways—VEGFA—colon cancer	1.15e-06	5.25e-06	CbGpPWpGaD
Bosutinib—EGFR—Signaling Pathways—CCND1—colon cancer	1.15e-06	5.23e-06	CbGpPWpGaD
Bosutinib—ERBB3—Signaling Pathways—AKT1—colon cancer	1.15e-06	5.22e-06	CbGpPWpGaD
Bosutinib—FYN—Signaling Pathways—NRAS—colon cancer	1.15e-06	5.21e-06	CbGpPWpGaD
Bosutinib—FYN—Immune System—AKT1—colon cancer	1.15e-06	5.21e-06	CbGpPWpGaD
Bosutinib—YES1—Signaling Pathways—HRAS—colon cancer	1.14e-06	5.19e-06	CbGpPWpGaD
Bosutinib—MAP2K1—Signaling Pathways—NRAS—colon cancer	1.14e-06	5.18e-06	CbGpPWpGaD
Bosutinib—MAP2K1—Immune System—AKT1—colon cancer	1.14e-06	5.18e-06	CbGpPWpGaD
Bosutinib—EGFR—Signaling Pathways—CTNNB1—colon cancer	1.14e-06	5.18e-06	CbGpPWpGaD
Bosutinib—LCK—Signaling Pathways—CASP3—colon cancer	1.14e-06	5.18e-06	CbGpPWpGaD
Bosutinib—MAP2K2—Signaling Pathways—MYC—colon cancer	1.14e-06	5.16e-06	CbGpPWpGaD
Bosutinib—IRAK1—Signaling Pathways—TP53—colon cancer	1.13e-06	5.15e-06	CbGpPWpGaD
Bosutinib—MAP2K2—Signaling Pathways—TGFB1—colon cancer	1.13e-06	5.15e-06	CbGpPWpGaD
Bosutinib—SRC—Immune System—KRAS—colon cancer	1.13e-06	5.11e-06	CbGpPWpGaD
Bosutinib—MAP2K2—Disease—AKT1—colon cancer	1.12e-06	5.11e-06	CbGpPWpGaD
Bosutinib—SRC—Disease—MYC—colon cancer	1.12e-06	5.11e-06	CbGpPWpGaD
Bosutinib—SRC—Disease—TGFB1—colon cancer	1.12e-06	5.1e-06	CbGpPWpGaD
Bosutinib—EGFR—Immune System—HRAS—colon cancer	1.12e-06	5.09e-06	CbGpPWpGaD
Bosutinib—EGFR—Disease—PIK3CA—colon cancer	1.12e-06	5.08e-06	CbGpPWpGaD
Bosutinib—EGFR—Signaling Pathways—CDKN1A—colon cancer	1.11e-06	5.06e-06	CbGpPWpGaD
Bosutinib—MAP2K2—Signaling Pathways—EGFR—colon cancer	1.11e-06	5.05e-06	CbGpPWpGaD
Bosutinib—LCK—Signaling Pathways—CCND1—colon cancer	1.11e-06	5.04e-06	CbGpPWpGaD
Bosutinib—PDGFRB—Signaling Pathways—MYC—colon cancer	1.11e-06	5.04e-06	CbGpPWpGaD
Bosutinib—PDGFRB—Signaling Pathways—TGFB1—colon cancer	1.11e-06	5.02e-06	CbGpPWpGaD
Bosutinib—MAP3K7—Signaling Pathways—PIK3CA—colon cancer	1.1e-06	5.01e-06	CbGpPWpGaD
Bosutinib—SRC—Disease—EGFR—colon cancer	1.1e-06	5e-06	CbGpPWpGaD
Bosutinib—LCK—Signaling Pathways—CTNNB1—colon cancer	1.1e-06	4.99e-06	CbGpPWpGaD
Bosutinib—PDGFRB—Disease—AKT1—colon cancer	1.1e-06	4.99e-06	CbGpPWpGaD
Bosutinib—LYN—Signaling Pathways—MYC—colon cancer	1.08e-06	4.93e-06	CbGpPWpGaD
Bosutinib—IRAK1—Signaling Pathways—HRAS—colon cancer	1.08e-06	4.93e-06	CbGpPWpGaD
Bosutinib—PDGFRB—Signaling Pathways—EGFR—colon cancer	1.08e-06	4.93e-06	CbGpPWpGaD
Bosutinib—EGFR—Signaling by GPCR—AKT1—colon cancer	1.08e-06	4.92e-06	CbGpPWpGaD
Bosutinib—LYN—Signaling Pathways—TGFB1—colon cancer	1.08e-06	4.92e-06	CbGpPWpGaD
Bosutinib—LCK—Immune System—HRAS—colon cancer	1.08e-06	4.91e-06	CbGpPWpGaD
Bosutinib—LCK—Disease—PIK3CA—colon cancer	1.08e-06	4.9e-06	CbGpPWpGaD
Bosutinib—LCK—Signaling Pathways—CDKN1A—colon cancer	1.07e-06	4.87e-06	CbGpPWpGaD
Bosutinib—FYN—Signaling Pathways—MYC—colon cancer	1.07e-06	4.85e-06	CbGpPWpGaD
Bosutinib—MAP3K7—Signaling Pathways—TP53—colon cancer	1.07e-06	4.85e-06	CbGpPWpGaD
Bosutinib—FYN—Signaling Pathways—TGFB1—colon cancer	1.07e-06	4.84e-06	CbGpPWpGaD
Bosutinib—MAP2K1—Signaling Pathways—MYC—colon cancer	1.06e-06	4.83e-06	CbGpPWpGaD
Bosutinib—LYN—Signaling Pathways—EGFR—colon cancer	1.06e-06	4.82e-06	CbGpPWpGaD
Bosutinib—MAP2K1—Signaling Pathways—TGFB1—colon cancer	1.06e-06	4.82e-06	CbGpPWpGaD
Bosutinib—EGFR—Signaling Pathways—EP300—colon cancer	1.06e-06	4.81e-06	CbGpPWpGaD
Bosutinib—FYN—Disease—AKT1—colon cancer	1.06e-06	4.81e-06	CbGpPWpGaD
Bosutinib—MAP2K1—Disease—AKT1—colon cancer	1.05e-06	4.78e-06	CbGpPWpGaD
Bosutinib—MAP2K2—Signaling Pathways—KRAS—colon cancer	1.05e-06	4.77e-06	CbGpPWpGaD
Bosutinib—FYN—Signaling Pathways—EGFR—colon cancer	1.04e-06	4.75e-06	CbGpPWpGaD
Bosutinib—MAP2K1—Signaling Pathways—EGFR—colon cancer	1.04e-06	4.72e-06	CbGpPWpGaD
Bosutinib—SRC—Disease—KRAS—colon cancer	1.04e-06	4.72e-06	CbGpPWpGaD
Bosutinib—EGFR—Disease—HRAS—colon cancer	1.03e-06	4.7e-06	CbGpPWpGaD
Bosutinib—SRC—Immune System—PIK3CA—colon cancer	1.03e-06	4.7e-06	CbGpPWpGaD
Bosutinib—EGFR—Signaling Pathways—SRC—colon cancer	1.03e-06	4.68e-06	CbGpPWpGaD
Bosutinib—PDGFRB—Signaling Pathways—KRAS—colon cancer	1.02e-06	4.65e-06	CbGpPWpGaD
Bosutinib—PTK2—Signaling Pathways—AKT1—colon cancer	1.02e-06	4.65e-06	CbGpPWpGaD
Bosutinib—MAP3K7—Signaling Pathways—HRAS—colon cancer	1.02e-06	4.64e-06	CbGpPWpGaD
Bosutinib—LCK—Signaling Pathways—EP300—colon cancer	1.02e-06	4.64e-06	CbGpPWpGaD
Bosutinib—YES1—Signaling Pathways—AKT1—colon cancer	1.01e-06	4.59e-06	CbGpPWpGaD
Bosutinib—SRC—Signaling Pathways—CASP3—colon cancer	1.01e-06	4.58e-06	CbGpPWpGaD
Bosutinib—EGFR—Signaling Pathways—VEGFA—colon cancer	1e-06	4.56e-06	CbGpPWpGaD
Bosutinib—LYN—Signaling Pathways—KRAS—colon cancer	1e-06	4.56e-06	CbGpPWpGaD
Bosutinib—LCK—Disease—HRAS—colon cancer	9.97e-07	4.53e-06	CbGpPWpGaD
Bosutinib—LCK—Signaling Pathways—SRC—colon cancer	9.92e-07	4.51e-06	CbGpPWpGaD
Bosutinib—EGFR—Signaling Pathways—NRAS—colon cancer	9.91e-07	4.5e-06	CbGpPWpGaD
Bosutinib—EGFR—Immune System—AKT1—colon cancer	9.9e-07	4.5e-06	CbGpPWpGaD
Bosutinib—FYN—Signaling Pathways—KRAS—colon cancer	9.87e-07	4.48e-06	CbGpPWpGaD
Bosutinib—MAP2K1—Signaling Pathways—KRAS—colon cancer	9.82e-07	4.46e-06	CbGpPWpGaD
Bosutinib—SRC—Signaling Pathways—CCND1—colon cancer	9.81e-07	4.46e-06	CbGpPWpGaD
Bosutinib—ABCB1—Metabolism—PPARG—colon cancer	9.77e-07	4.44e-06	CbGpPWpGaD
Bosutinib—SRC—Signaling Pathways—CTNNB1—colon cancer	9.72e-07	4.42e-06	CbGpPWpGaD
Bosutinib—LCK—Signaling Pathways—VEGFA—colon cancer	9.67e-07	4.39e-06	CbGpPWpGaD
Bosutinib—MAP2K2—Signaling Pathways—PIK3CA—colon cancer	9.64e-07	4.38e-06	CbGpPWpGaD
Bosutinib—IRAK1—Signaling Pathways—AKT1—colon cancer	9.57e-07	4.35e-06	CbGpPWpGaD
Bosutinib—SRC—Immune System—HRAS—colon cancer	9.56e-07	4.35e-06	CbGpPWpGaD
Bosutinib—LCK—Signaling Pathways—NRAS—colon cancer	9.55e-07	4.34e-06	CbGpPWpGaD
Bosutinib—SRC—Disease—PIK3CA—colon cancer	9.54e-07	4.34e-06	CbGpPWpGaD
Bosutinib—LCK—Immune System—AKT1—colon cancer	9.54e-07	4.33e-06	CbGpPWpGaD
Bosutinib—SRC—Signaling Pathways—CDKN1A—colon cancer	9.49e-07	4.31e-06	CbGpPWpGaD
Bosutinib—PDGFRB—Signaling Pathways—PIK3CA—colon cancer	9.41e-07	4.27e-06	CbGpPWpGaD
Bosutinib—MAP2K2—Signaling Pathways—TP53—colon cancer	9.33e-07	4.24e-06	CbGpPWpGaD
Bosutinib—EGFR—Signaling Pathways—MYC—colon cancer	9.23e-07	4.19e-06	CbGpPWpGaD
Bosutinib—LYN—Signaling Pathways—PIK3CA—colon cancer	9.21e-07	4.19e-06	CbGpPWpGaD
Bosutinib—EGFR—Signaling Pathways—TGFB1—colon cancer	9.21e-07	4.18e-06	CbGpPWpGaD
Bosutinib—EGFR—Disease—AKT1—colon cancer	9.14e-07	4.15e-06	CbGpPWpGaD
Bosutinib—PDGFRB—Signaling Pathways—TP53—colon cancer	9.1e-07	4.14e-06	CbGpPWpGaD
Bosutinib—FYN—Signaling Pathways—PIK3CA—colon cancer	9.07e-07	4.12e-06	CbGpPWpGaD
Bosutinib—SRC—Signaling Pathways—EP300—colon cancer	9.03e-07	4.11e-06	CbGpPWpGaD
Bosutinib—MAP2K1—Signaling Pathways—PIK3CA—colon cancer	9.02e-07	4.1e-06	CbGpPWpGaD
Bosutinib—MAP3K7—Signaling Pathways—AKT1—colon cancer	9.01e-07	4.09e-06	CbGpPWpGaD
Bosutinib—MAP2K2—Signaling Pathways—HRAS—colon cancer	8.92e-07	4.05e-06	CbGpPWpGaD
Bosutinib—LYN—Signaling Pathways—TP53—colon cancer	8.91e-07	4.05e-06	CbGpPWpGaD
Bosutinib—LCK—Signaling Pathways—MYC—colon cancer	8.89e-07	4.04e-06	CbGpPWpGaD
Bosutinib—LCK—Signaling Pathways—TGFB1—colon cancer	8.87e-07	4.03e-06	CbGpPWpGaD
Bosutinib—SRC—Disease—HRAS—colon cancer	8.83e-07	4.01e-06	CbGpPWpGaD
Bosutinib—LCK—Disease—AKT1—colon cancer	8.81e-07	4e-06	CbGpPWpGaD
Bosutinib—FYN—Signaling Pathways—TP53—colon cancer	8.77e-07	3.99e-06	CbGpPWpGaD
Bosutinib—MAP2K1—Signaling Pathways—TP53—colon cancer	8.72e-07	3.96e-06	CbGpPWpGaD
Bosutinib—PDGFRB—Signaling Pathways—HRAS—colon cancer	8.7e-07	3.95e-06	CbGpPWpGaD
Bosutinib—LCK—Signaling Pathways—EGFR—colon cancer	8.7e-07	3.95e-06	CbGpPWpGaD
Bosutinib—CYP3A4—Metabolism—ABCB1—colon cancer	8.65e-07	3.93e-06	CbGpPWpGaD
Bosutinib—SRC—Signaling Pathways—VEGFA—colon cancer	8.56e-07	3.89e-06	CbGpPWpGaD
Bosutinib—EGFR—Signaling Pathways—KRAS—colon cancer	8.53e-07	3.87e-06	CbGpPWpGaD
Bosutinib—LYN—Signaling Pathways—HRAS—colon cancer	8.52e-07	3.87e-06	CbGpPWpGaD
Bosutinib—CYP3A4—Metabolism—TYMS—colon cancer	8.5e-07	3.86e-06	CbGpPWpGaD
Bosutinib—SRC—Signaling Pathways—NRAS—colon cancer	8.45e-07	3.84e-06	CbGpPWpGaD
Bosutinib—SRC—Immune System—AKT1—colon cancer	8.44e-07	3.84e-06	CbGpPWpGaD
Bosutinib—FYN—Signaling Pathways—HRAS—colon cancer	8.39e-07	3.81e-06	CbGpPWpGaD
Bosutinib—MAP2K1—Signaling Pathways—HRAS—colon cancer	8.34e-07	3.79e-06	CbGpPWpGaD
Bosutinib—LCK—Signaling Pathways—KRAS—colon cancer	8.22e-07	3.73e-06	CbGpPWpGaD
Bosutinib—MAP2K2—Signaling Pathways—AKT1—colon cancer	7.87e-07	3.58e-06	CbGpPWpGaD
Bosutinib—SRC—Signaling Pathways—MYC—colon cancer	7.87e-07	3.58e-06	CbGpPWpGaD
Bosutinib—SRC—Signaling Pathways—TGFB1—colon cancer	7.85e-07	3.57e-06	CbGpPWpGaD
Bosutinib—EGFR—Signaling Pathways—PIK3CA—colon cancer	7.83e-07	3.56e-06	CbGpPWpGaD
Bosutinib—SRC—Disease—AKT1—colon cancer	7.8e-07	3.54e-06	CbGpPWpGaD
Bosutinib—SRC—Signaling Pathways—EGFR—colon cancer	7.7e-07	3.5e-06	CbGpPWpGaD
Bosutinib—ABCB1—Metabolism—PTGS2—colon cancer	7.69e-07	3.49e-06	CbGpPWpGaD
Bosutinib—PDGFRB—Signaling Pathways—AKT1—colon cancer	7.68e-07	3.49e-06	CbGpPWpGaD
Bosutinib—EGFR—Signaling Pathways—TP53—colon cancer	7.58e-07	3.44e-06	CbGpPWpGaD
Bosutinib—LCK—Signaling Pathways—PIK3CA—colon cancer	7.55e-07	3.43e-06	CbGpPWpGaD
Bosutinib—LYN—Signaling Pathways—AKT1—colon cancer	7.52e-07	3.42e-06	CbGpPWpGaD
Bosutinib—FYN—Signaling Pathways—AKT1—colon cancer	7.41e-07	3.37e-06	CbGpPWpGaD
Bosutinib—MAP2K1—Signaling Pathways—AKT1—colon cancer	7.37e-07	3.35e-06	CbGpPWpGaD
Bosutinib—LCK—Signaling Pathways—TP53—colon cancer	7.3e-07	3.32e-06	CbGpPWpGaD
Bosutinib—SRC—Signaling Pathways—KRAS—colon cancer	7.27e-07	3.31e-06	CbGpPWpGaD
Bosutinib—EGFR—Signaling Pathways—HRAS—colon cancer	7.25e-07	3.29e-06	CbGpPWpGaD
Bosutinib—LCK—Signaling Pathways—HRAS—colon cancer	6.98e-07	3.17e-06	CbGpPWpGaD
Bosutinib—SRC—Signaling Pathways—PIK3CA—colon cancer	6.68e-07	3.04e-06	CbGpPWpGaD
Bosutinib—SRC—Signaling Pathways—TP53—colon cancer	6.47e-07	2.94e-06	CbGpPWpGaD
Bosutinib—EGFR—Signaling Pathways—AKT1—colon cancer	6.4e-07	2.91e-06	CbGpPWpGaD
Bosutinib—ABCB1—Metabolism—EP300—colon cancer	6.39e-07	2.9e-06	CbGpPWpGaD
Bosutinib—SRC—Signaling Pathways—HRAS—colon cancer	6.18e-07	2.81e-06	CbGpPWpGaD
Bosutinib—LCK—Signaling Pathways—AKT1—colon cancer	6.17e-07	2.8e-06	CbGpPWpGaD
Bosutinib—CYP3A4—Metabolism—PPARG—colon cancer	6.02e-07	2.74e-06	CbGpPWpGaD
Bosutinib—SRC—Signaling Pathways—AKT1—colon cancer	5.46e-07	2.48e-06	CbGpPWpGaD
Bosutinib—CYP3A4—Metabolism—PTGS2—colon cancer	4.74e-07	2.15e-06	CbGpPWpGaD
Bosutinib—ABCB1—Metabolism—PIK3CA—colon cancer	4.73e-07	2.15e-06	CbGpPWpGaD
Bosutinib—CYP3A4—Metabolism—EP300—colon cancer	3.94e-07	1.79e-06	CbGpPWpGaD
Bosutinib—ABCB1—Metabolism—AKT1—colon cancer	3.86e-07	1.76e-06	CbGpPWpGaD
Bosutinib—CYP3A4—Metabolism—PIK3CA—colon cancer	2.91e-07	1.32e-06	CbGpPWpGaD
Bosutinib—CYP3A4—Metabolism—AKT1—colon cancer	2.38e-07	1.08e-06	CbGpPWpGaD
